CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Novavax boosts 2026 revenue forecast as licensing deals pay off

By Reuters News

By Sriparna Roy

Nov 5 (Reuters) - Vaccine maker Novavax NVAX.O raised its annual revenue forecast above Wall Street expectations on ​Thursday, banking on payments related to its licensing deals.

The company has relied on licensing deals and partnerships tied to its protein-based vaccine platform and its Matrix-M vaccine adjuvant — a compound that boosts the body's immune response to vaccines.

Novavax now expects 2026 adjusted revenue between $385 million and $415 million, higher than $235 million to $275 million previously and analysts' average estimate of $380.29 million, according to data compiled by LSEG.

The loss-making company is betting on the licensing agreement with French drugmaker Sanofi SASY.PA, ​worth at least $1.2 billion, to reach profitability by 2028.

"We intend to bring new partners forward and it is core to our business model. So not only are we open to it, but we proactively try to facilitate and seek that," Novavax CEO John Jacobs said in an interview.

The company is running experiments to assess the impact of adding its Matrix-M adjuvant to existing shots, having evaluated more than 30 commercialized vaccines globally, Jacobs told Reuters.

Sanofi plans a late-stage US trial of its influenza-COVID-19 combination vaccine, which uses Novavax's COVID-19 vaccine Nuvaxovid, in 2027. Novavax is eligible for a milestone payment of $225 million upon US commercial launch.

https://www.reuters.com/graphics/NOVAVAX-RESULTS/NOVAVAX-RESULTS/lgpdbyelypo/chart.png

The Democrats' sweep in the US midterm elections has lifted hopes of stability in vaccine policy after a period of uncertainty.

"I think it's too early to tell in the immediacy what may exactly happen there ... I do think that could bode well over time for vaccine manufacturers," Jacobs said.

Novavax is also exploring vaccines for bacterial and fungal infections, as well as cancer.

It posted a quarterly net loss of $31 million, compared with a net loss of $202 million a year ago.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.